stockmarket

Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment




By Sam Boughedda

Investing.com — Biotechnology company Nanobiotix (NASDAQ:) shares rallied 23% on Thursday after it revealed after Wednesday’s closing bell that it has enrolled the first patient in a phase 3 study of its treatment for head and neck cancer.

The study is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 in high-risk, chemotherapy-ineligible elderly patients with locally advanced head and neck cancer. The trial follows on from the Nanobiotix Study 102, a phase 1 trial evaluating safety and early signs of efficacy.

The U.S. Food and Drug Administration has granted Fast Track designation to investigate radiotherapy-activated NBTXR3, giving it the opportunity for priority review and accelerated approval.

“The first patient enrolled in our global phase III study is a testament to the tireless commitment of our team, investigators, and strategic collaborators,” said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.